Krister Wennerberg

Krister Wennerberg

Professor

Member of:


    1. 2014
    2. A community effort to assess and improve drug sensitivity prediction algorithms

      NCI DREAM Community, N. D. C., Dec 2014, In: Nature Biotechnology. 32, 12, p. 1202-12 11 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    3. Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening

      Vidugiriene, J., Leippe, D., Sobol, M., Vidugiris, G., Zhou, W., Meisenheimer, P., Gautam, P., Wennerberg, Krister & Cali, J. J., 17 Dec 2014, In: ASSAY and Drug Development Technologies. 12, 9-10, p. 514-26 13 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    4. 2015
    5. Discovery of MINC1, a GTPase-activating protein small molecule inhibitor, targeting MgcRacGAP

      van Adrichem, A. J., Fagerholm, A., Turunen, L., Lehto, A., Saarela, J., Koskinen, A., Repasky, G. A. & Wennerberg, Krister, 2015, In: Combinatorial Chemistry & High Throughput Screening. 18, 1, p. 3-17 15 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    6. KIFC1 is a novel potential therapeutic target for breast cancer

      Li, Y., Lu, W., Chen, D., Boohaker, R. J., Zhai, L., Padmalayam, I., Wennerberg, Krister, Xu, B. & Zhang, W., 2015, In: Cancer Biology & Therapy. 16, 9, p. 1316-22 7 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    7. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model

      Yadav, B., Wennerberg, Krister, Aittokallio, T. & Tang, J., 2015, In: Computational and Structural Biotechnology Journal. 13, p. 504-13 10 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    8. What is synergy? The Saariselkä agreement revisited

      Tang, J., Wennerberg, Krister & Aittokallio, T., 2015, In: Frontiers in Pharmacology. 6, p. 181

      Research output: Contribution to journalReviewResearchpeer-review

    9. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

      Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., Murray, B. W. & Wennerberg, Krister, 5 Mar 2015, In: Nature. 519, 7541, p. 102-5 4 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    10. TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples

      He, L., Wennerberg, Krister, Aittokallio, T. & Tang, J., 1 Jun 2015, In: Bioinformatics (Online). 31, 11, p. 1866-8 3 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    11. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products

      Kibble, M., Saarinen, N., Tang, J., Wennerberg, Krister, Mäkelä, S. & Aittokallio, T., Aug 2015, In: Natural Product Reports. 32, 8, p. 1249-66 18 p.

      Research output: Contribution to journalReviewResearchpeer-review

    12. Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles

      Szwajda, A., Gautam, P., Karhinen, L., Jha, S. K., Saarela, J., Shakyawar, S., Turunen, L., Yadav, B., Tang, J., Wennerberg, Krister & Aittokallio, T., 20 Aug 2015, In: Chemistry & Biology. 22, 8, p. 1144-55 12 p.

      Research output: Contribution to journalJournal articleResearchpeer-review

    Previous 1 2 3 4 5 6 7 8 ...13 Next

    ID: 181406515